Current and future therapeutic options for the management of gout

Andrew Whelton

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.

Original languageEnglish (US)
Pages (from-to)402-417
Number of pages16
JournalAmerican Journal of Therapeutics
Issue number4
StatePublished - Jul 2010


  • febuxostat
  • gout
  • hyperuricemia
  • uricase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • General Medicine


Dive into the research topics of 'Current and future therapeutic options for the management of gout'. Together they form a unique fingerprint.

Cite this